Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-Staphylococcus aureus ostrich antibody emulsion is a topical biologic therapy developed by Zeal Cosmetics for the treatment of atopic dermatitis. The formulation contains polyclonal immunoglobulin Y (IgY) antibodies extracted from the egg yolks of ostriches that have been immunized against *Staphylococcus aureus*. In patients with atopic dermatitis, *S. aureus* colonization is a major driver of skin inflammation and barrier dysfunction. By topically applying these antibodies, the drug aims to specifically neutralize *S. aureus* and its toxins on the skin surface, thereby reducing inflammatory triggers and restoring the skin's natural microbiome balance without the use of traditional antibiotics. It is currently being evaluated in clinical trials as an adjunctive treatment for patients with treatment-resistant lesions, including those already receiving systemic therapies like dupilumab.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Staphylococcus aureus ostrich antibody emulsion.